A leading telemental health platform in China using technology to help people thrive in a stigma free and empowering environment with wide access to the most professional and warm-hearted psychiatrists and therapists.

A leading Asian food delivery platform in North America, with No.1 market share in Canada.

• Participated in-depth in the daily operation and management of AccuraGen, one of Decheng's portfolio company• Participated in-depth in below three investment projects by conducting comprehensive financial, business and legal due diligence, building financial model and drafting investment documents:– Series A financing of an innovative interventional cardiovascular diagnostics device provider in China – Series B+ financing of a US-China cross-border leading ingredient vegetables supplier – Pre-IPO investment in a leading supplier of minimally invasive spine surgery devices in China • Led comprehensive research of over 50 listed companies in various healthcare industry sectors including biophama, medical device, diagnostics and life science tools • Assisted in reviewing investment opportunities in over 400 companies and established databases for M&A and IPO transactions; Maintained daily deal logs

AccuraGen develops ctDNA liquid biopsy products for cancer diagnostic and is a portfolio company of Decheng Capital. It has raised in total around $50 million funding since it started.• Built monthly and multi-year operational and financial model from scratch to guide corporate sales and expense budget planning, monitor cash flow, guide corporate valuation and identify future financing needs • Actively supported business strategy assessment and implementation through efforts below:– Conducted in-depth industry research and built a multi-year market forecast model to calculate addressable market potential in each target sector and identify business opportunities accordingly– Assisted in product positioning strategy decisions through competitive landscape analysis in technology differentiation, product portfolio, target customers, sales channel and product pricing – Prepared formal presentations based on both quantitative and qualitative analysis to recommend business strategies to board members and management team• Led corporate financing and M&A efforts through communicating with potential investors, preparing financing presentations, due diligence materials and valuation model

Leading medical device player in intravascular diagnostic tools including FFR, IVUS and OCT. The company's FFR microcatheter system has obtained CE mark and is also the first to get NMPA Class III approval in China.

• Played a crucial role in the privatization of Singapore-listed medtech company Biosensors International Group: – Evaluated the fairness of offer price via various valuation methodologies– Built LBO model to guide company valuation and conducted return analysis under different valuation scenarios– Prepared transaction documents including co-investor & debt financing communication materials and client internal investment committee proposal • Participated in several IPO deals for companies in various sectors including medical device, healthcare service and pharmaceuticals:– Prepared transaction documents including IPO filing package, selling memo, IPO prospectus, analyst presentation and roadshow presentation and built IPO financial & pricing model • Participated in several transactions including: private placement for a specialty pharmaceutical company and a leading digital healthcare company; restructuring of the largest Chinese conglomerate F&B company; secondary sell-down and follow-on offering transactions for several HK-listed Chinese healthcare companies • Daily deskwork including: pitch book preparation for HK IPO, M&A and take-private transactions; maintenance of trading comparables, M&A database and corporate profiles etc.